Arizona rancher George Kelly, who was freed after a mistrial in a murder case, said he fired warning shots when men approached his home with a gun.

Former President Donald Trump slammed the "radical left lunatics" on college campuses nationwide for creating chaos amid their protests against Israel.

Seven of the eight House Republicans who ousted ex House Speaker Kevin McCarthy are still serving in Congress, and nearly all of them are outright opposed to ousting House Speaker Mike Johnson right now.

Israeli President Isaac Herzog weighed in on the massive antisemitic encampments that have sprouted up at elite US colleges and universities, such as UCLA and Columbia.

Still searching for the perfect Mother’s Day gift? Sarah Gelman, Amazon Books Editorial Director, shares her top book picks for all kinds of moms.

Russia introduced a U.N. resolution to ban all weapons in outer space for all time just a week after vetoing a similar proposal from the United States and Japan.

O'Donnell shared a photo of a script for season three, episode one of the Max show, revealing her character's name is Mary.

It takes a certain amount of confidence to call your biotech company Grail. According to its website, the Menlo Park–based firm got its name because its “co-founders believed a simple blood test could be the ‘holy GRAIL’ of cancer detection.” Now the company claims that its “first-of-its-kind” screening tool, called Galleri, “redefines what’s possible.” At the cost of a needle stick and $949, the company can check your blood for more than 50 forms of cancer all at once.The Galleri test, as well as many others of its type that are in development, is meant to sniff out malignant DNA floating in a person’s veins, including bits of tumors that otherwise might not be identified until they’ve spread. But the rapid introduction of this new technology, which is now available through major U.S. health systems, isn’t really guaranteed to help patients. Indeed, a contentious debate about its potential benefits has been playing out in the scientific literature for the past few years. Multi-cancer-screening tools—or “cancer-finding supertests,” as Galleri has been called—aren’t yet endorsed by the U.S. Preventive Services Task Force, or formally approved by the Food and Drug Administration. For the moment, health-care providers can offer Galleri only through a commonly used regulatory loophole that the government is desperately trying to close. Being able to distribute the company’s “prescription-only, well-validated test” in advance of full FDA approval is a good thing, Kristen Davis, a Grail spokesperson told me, because it gives patients “timely access to an important tool in the detection of unscreened cancers and allows for important real-world evidence collection.” That’s one way to look at it. Here’s another: The rush to get Galleri and related products into doctors’ offices skips right over the most important step in clinical development: proving that they really work.“The status quo for cancer screening remains unacceptable,” Davis said. She’s right. Even traditional early-detection tests are controversial within the medical community. As a hospital pathologist who diagnoses cancer daily, I’ve seen firsthand how mammograms and Pap smears, among other traditional procedures, save some people’s lives—and also how they cause a lot of overtreatment. (They miss many lethal cancers, too.) Blood-based cancer screening, in particular, had an ignominious start. Most men middle-aged and older in the U.S. get PSA tests, which look for abnormal levels of a protein secreted from the prostate gland that may indicate malignancy. But many of the tumors those tests identify are slow-growing, harmless ones; their discovery leads to an epidemic of unnecessary surgery and radiation—and a subsequent epidemic of incontinence and impotence. Recognizing this harm, the scientist who first identified PSA more than half a century ago expressed his regret in 2010, calling widespread screening “a profit-driven public health disaster.”Modern blood-based cancer tests (or “liquid biopsies”), which look for a tumor’s genetic material, have been more promising. The first was approved by the FDA in 2016. It allows patients who already know that they have lung cancer to avoid an invasive tissue-collection process while still receiving the right, targeted therapy for their particular disease. Today, liquid biopsies exist for other kinds of cancer, too, and are used to tailor treatment for people who are aware of being sick.Unleashing the same technique on the general population, in an effort to find hidden cancers in healthy-seeming people, is in principle a reasonable idea. But in 2020, when Grail started trying its technology on thousands of adults without cancer symptoms, the company found that a majority of positive signals—the signs of potential tumors that it identified—weren’t real. Dozens of healthy participants were flagged as possibly having cancer; most suffered through unnecessary laboratory and imaging follow-up. One unlucky subject described in the published study even had his testicle removed in the hunt for a malignancy that didn’t exist. Another blood-based supertest called CancerSeek—which forms the basis of a multi-cancer test now under commercial development—had shown the same problem when an early iteration of it was studied in some 10,000 women: Registered blood “abnormalities” led to confirmed cancer diagnoses less than half of the time. False positives with CancerSeek caused some patients to have operations on their ovaries, colon, or appendix.No form of cancer screening will be perfect, and Davis pointed out that “when used as recommended, in addition to current single-cancer screenings, the Galleri test can help screen for some of the deadliest cancers that often come with no warning today.” For cancers of the pancreas, ovaries, esophagus, and liver, she suggested, any form of screening will be better than what we currently have: nothing. Grail researchers have also noted that its technology “compares favourably” to other, more familiar single-cancer tests in the sense that a smaller proportion of patients end up with spurious results. (One in 200 people will experience a false positive with Galleri, while the same is true for about one in 10 women who get a mammogram.)But an imperfect screening tool is not always better than no screening tool at all. We already have reasonably accurate early-detection tests for pancreatic and ovarian cancer, for example, but experts recommend against their widespread use because—counterintuitively—screening healthy patients does little to extend their lives and comes with its own harms. And although it is true that Galleri’s false-positive rate is quite good in comparison to those of mammograms, PSA tests, and Pap smears, that’s only half the story. A glitchy answer from a cancer supertest like Grail’s may well be worse than the equivalent mistake in, say, a breast exam. The latter would only lead to further hunting for a tumor in the breast—perhaps with an ultrasound or MRI. In contrast, the follow-up for a suspect finding from a screen for 50 different cancers could be body-wide, producing yet more ambiguous results—such as the discovery of kidney cysts or lung nodules—that generate their own tests and surgeries.When Galleri finds a potential tumor, it does provide doctors with some hints as to where that tumor might be located. In practice, though, doctors will likely err on the side of running lots of tests. Positive signals are often followed by a PET-CT scan, for example, which costs about $2,500 and exposes people to 62 times the radiation of a mammogram. In Grail’s own research, participants who received a false-positive result were generally subjected to multiple additional lab and imaging tests—sometimes as many as 16 laboratory studies and 10 clinic visits.[Read: When cancer screening stopped]More thorough and extensive testing takes longer, too. An errant mammogram might be resolved fairly quickly, with conclusive follow-up testing done a few weeks later. The equivalent delay after an abnormal Pap smear is less than two months, generally speaking. In the aftermath of multi-cancer blood-test screenings, though, worried patients may have to bide their time for almost half a year before a doctor reassures them that they do not, in fact, have cancer. Subjects in Grail’s study who received a false-positive result spent an average of 162 days in suspense before being cleared.When I asked Grail about potential harms of the test, including this delay, the spokesperson told me that Galleri offers diagnostic guidance for doctors and patients who test positive through “a suite of services, including direct support from our medical science liaisons.” Grail has also presented data suggesting that the distress of patients who receive false positives tends to go away over time. Some people, however, may never feel completely at ease knowing that cancer-related genetic code is circulating in their veins. The medical system is very good at puncturing patients’ confidence in their own health.Some anxiety may be worth experiencing for the opportunity to catch an actual cancer before it turns fatal. But that exchange would only work if curable cancers could be consistently picked up in our blood. Galleri is much better at detecting advanced malignancies—which shed more genetic material, and many of which are incurable—than small ones that are worth finding sooner. Galleri is billed as an early-detection test, but just one out of five cancers it finds are identified at Stage 1, which is the earliest stage. At this point, the same is true for other blood-based screening strategies, as well.[Read: Theranos and COVID-19 testing are mirror-image cautionary tales]The only way to know for sure whether cancer-finding supertests truly save lives is to evaluate them in a large randomized, controlled trial. The U.K.’s National Health Service has enrolled 140,000 participants in such a study of Galleri; the main results, on whether the test can find cancers before they spread, are expected in a year or two. Then researchers will keep track of whether participants have their lives extended in the years that follow. In the meantime, U.S. efforts are running far behind. The National Cancer Institute is planning for a 24,000-person pilot study of multi-cancer screening, but any bigger and more useful randomized trial won’t begin for a long time.The fact that all of this research is ongoing hasn’t stopped Grail from offering its wares to the public. The company recently sponsored a PGA Champions Tour event in California, where players and fans were offered cancer-screening blood tests on the golf course at a $100 discount; more than 100,000 Galleri tests have been performed in the U.S. since they first became commercially available. Meanwhile, hundreds of advocacy groups are lobbying the government to pay for multi-cancer-screening tests through Medicare. By one estimate, widespread adoption could cost Americans more than $100 billion annually—dwarfing the $7.8 billion spent on mammograms as of 2010, or the $6.6 billion spent on Pap smears.It’s hard to miss the scientific challenge that still remains. In what might be a bit of corporate retconning, when Barron’s spoke with one of Grail’s co-founders about the story behind the company’s name in 2021, he wasn’t quoted saying that the company thought its blood test could be the holy grail of cancer screening. Rather, he said the name was chosen “out of humility,” because “the Holy Grail was never found.” That humility isn’t in the pitch to patients, though. Most people who use the product today will have no idea that they are generating “real-world evidence” for a technology that may yet be found unable to extend their lives. They’ll assume that if cancer-finding supertests are available in clinics, then we must already know that they’re worth using. We don’t.

Sedgwick didn't hold back on Watch What Happens Live. 

Oklahoma education chief Ryan Walters opposes The Satanic Temple's plan to place its ministers in schools after a bill passed the state House that would permit volunteer chaplains.

Mark Kerrison/In Pictures via Getty ImagesLaurence Fox, the controversial British actor-turned-political activist, could be facing a police investigation after he allegedly posted an explicit upskirt image of a broadcaster on X without her consent.Fox on Wednesday posted an old paparazzi shot showing Narinder Kaur sitting in a car without underwear on, according to The Daily Mirror. “This is now a police matter,” Kaur wrote in a post Thursday morning along with a link to an article about the incident.The image no longer appears on Fox’s X account as of Thursday morning. According to the Mirror, the photograph was taken without Kaur’s consent or knowledge and was scrubbed from online photo libraries after upskirting was made a criminal offense in Britain.Read more at The Daily Beast.

Country star Walker Hayes talks about his new album, "Sober Thoughts," and his journey toward sobriety.

The Duchess of Sussex, 42, has long been rumored to have been eyeing a career in politics.

More than 80 bands perform outdoors in Adams Morgan, Chihuahua races return to the Wharf, and Washington National Cathedral is in bloom during Flower Mart.

Police raided the anti-war encampment at UCLA, which was declared unlawful by university officials overnight. It came one day after a violent clash between protesters and counter-protesters.

Residents of two Lake County, Florida, communities have seen wild monkeys, capturing the rare occurrences on camera while reporting them to police.

Cannon's office say her sponsored trips to a Montana conference were declared

Conservatives raised concerns about Republicans voting for the Antisemitism Awareness Act.

For the first time since his New York criminal trial got underway, former President Donald Trump returned to campaigning on Wednesday, this time in Michigan and Wisconsin, which are two crucial battleground states in the 2024 election. On the campaign trail, he highlighted his role in overturning Roe v. Wade, and emphasized his opinion that abortion should be left to the states. Trump will be in court Thursday as his criminal trial resumes.

Iowa Gov. Kim Reynolds signed into law a bill which would cut the state's income tax starting on January 1, 2025.

The UCLA student encampment was swarmed by police overnight. This comes one day after the encampment was attacked by counter-protesters. Also, Texas faces major flooding after days of severe weather, with even more storms on the way. All that and all that matters in today’s Eye Opener.

Back in the day, Drew Barrymore kept a hard copy of all of the people she had a sexual relationship with. Barrymore admitted she left her "sex list" at Danny DeVito's house while working on a film.

Robert F. Kennedy Jr., the independent presidential candidate, sounded off Wednesday on 'Jesse Watters Primetime,' saying he'd defeat Trump or Biden head-to-head.

Broadcast news outlets throughout the world wanted to understand what happened at UCLA, where violence erupted at a pro-Palestinian student encampment.

"If there was beef, where was the beef cooked?"

This year’s field is headlined by No. 17 Fierceness (5-2), who won the Breeders’ Cup Juvenile at 16-1 odds, and No. 2 Sierra Leone (3-1).

Artists from Universal Music Group, which include Taylor Swift, Bad Bunny and Billie Eilish, will return to TikTok after the two parties struck an agreement.

Dressing like Tiger Woods is going to cost you.

Family members of a Boeing whistleblower, Joshua Dean, who died on Tuesday, posted messages of mourning on social media.

Approximately $5.5 million in restitution owed from a fraudulent family trust is still in the process of recovery by authorities.

This deal is heating up!

Trillions of cicadas are emerging across 12 states, from the Midwest to the East Coast, after spending more than a decade underground. In Central Illinois, there is a rare opportunity to see two types of cicadas together for the first time in more than 200 years.

UnitedHealth Group CEO Andrew Witty disclosed that a cyberattack on one of its subsidiaries earlier this year might affect up to a third of all Americans.

Amid ongoing airstrikes in Rafah, Gaza, demonstrators in Tel Aviv intensify calls for the Israeli government to negotiate a hostage deal with Hamas. The protests have included blocking traffic in Israel's second-largest city.

Swifties celebrated her reaction, with one gushing, "If Taylor Swift liking this doesn't validate you, I don't know what will you got the trophy!"

The Ukrainians have praised the effectiveness of the HIMARS systems, which can launch a variety of rockets.

The ECHR rejected an appeal of its ruling that Italy has the right to reclaim a prized bronze statue, nicknamed the “Getty Bronze," by the Getty Museum in California.

It is not Donald J. Trump who has come in for sustained criticism from witnesses. It is his former fixer, who paid the hush money at the heart of the case.

Dave Portnoy said he "panicked" when he realized he and 25-year-old Camryn D’Aloia were featured on the live broadcast Monday.

In the latest installment of our "Climate Watch" series, climate activists take bold measures, including blockading the entrance to Citigroup's global headquarters in Manhattan. Protesters are demanding the banking giant cease its funding of fossil fuels.

via OK.ru Russia appears to have two new poster children for its war against Ukraine and supposed crusade to save “traditional values” from the deviant West: a cannibal and a murderer united on the battlefield.Nearly two years after Moscow first hatched its deranged prison-recruitment scheme to use hardened criminals as cannon fodder in Ukraine, a selfie shared on social media provides a glimpse of the country’s new normal.Dmitry Malyshev, sentenced to 25 years in 2015 for murdering a man and filming himself eating the victim’s heart, among other things, can be seen grinning and embracing Alexander Maslennikov, who got 23 years for murdering and dismembering two women he met at a nightclub.Read more at The Daily Beast.

Peloton is cutting about 400 jobs worldwide as part of a restructuring effort and its CEO Barry McCarthy is stepping down after two years as the company continues to work on turning around its business

More than 16,000 pounds of ground beef sold at Walmart stores across the US have been recalled over a possible E. coli contamination, the US Department of Agriculture said. The beef comes from Cargill Meat Solutions in Hazleton, Pa., per a “high class” warning issued on the USDA’s site on Wednesday, and were “shipped to...

Former President Donald Trump's "hush money" trial resumes Thursday with another gag order hearing. On Wednesday, Trump slammed the judge in the case, telling supporters at a rally he had been "unconstitutionally gagged." CBS News investigative reporter Graham Kates has more on the case.

Columbia University and other private colleges should cough up and help foot the bill for the NYPD having to swarm the Ivy League campus and crackdown on unruly anti-Israel protests, Mayor Eric Adams said Thursday.

The most important fashion event of 2024 is almost upon us. Here's all you need to know ahead of the extravaganza.

The comedian shared a photo of her script for the premiere episode of the upcoming season on Instagram Wednesday.

Follow the Post’s live updates for the latest news, analysis and photos from the Trump trial in NYC.